Cardiovascular complications in patients with HIV infection

Current Infectious Disease Reports

Volumn 5, Issue 6, 2003, Pages 513-520

  Zareba, Karolina M ^b   Lipshultz, Steven E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD4 ANTIGEN; CHOLESTEROL; COTRIMOXAZOLE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; ERYTHROMYCIN; FOSCARNET SODIUM; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PENTAMIDINE; PRENYLAMINE; PROCAINAMIDE; PROSTACYCLIN; PSYCHOTROPIC AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; UNINDEXED DRUG; VASODILATOR AGENT;

ARTERY DISEASE; ATHEROSCLEROSIS; AUTONOMIC DYSFUNCTION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENDOCARDITIS; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEART TUMOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; INSULIN RESISTANCE; KAPOSI SARCOMA; LYMPHOMA; MYOCARDITIS; PATIENT CARE; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PNEUMOCYSTIS PNEUMONIA; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; TORSADE DES POINTES;

EID: 3142547345     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-003-0096-5     Document Type: Review

References (59)

1. AIDS Epidemic Update December 2002. http://www.unaids.org. Accessed February 12, 2003.
2. Bozzette SA, Ake CF, Tam HK, et al.: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702-710.
3. Lipshultz SE: Dilated cardiomyopathy in HIV-infected patients. N Engl J Med 1998, 339:1153-1155.
4. Felker GM, Thompson RE, Hare JM, et al.: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077-1084.
5. Lipshultz SE, Easley KA, Orav EJ, et al.: Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 1998, 97:1246-1256.
6. Lipshultz SE, Easley KA, Orav EJ, et al.: Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 2000, 102:1542-1548.
7. Starc TJ, Lipshultz SE, Easley KA, et al.: Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: the prospective P2C2 HIV study. J Pediatr 2002, 141:327-334.
8. Fisher SD, Lipshultz SE: Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann NY Acad Sci 2001, 946:13-22.
9. Fisher SD, Lipshultz SE: Cardiac disease. In AIDS Therapy, edn 2. Edited by Dolin R, Masur H, Saag MS. Philadelphia: Churchill-Livingstone; 2002:814-826.
10. Kasten-Sportes C, Weinstein C: Molecular mechanisms of HIV cardiovascular disease. In Cardiology in AIDS. Edited by Lipshultz SE. New York: Chapman and Hall; 1998:265-282.
11. Currie PF, Goldman JH, Caforio AL, et al.: Cardiac autoimmunity in HIV related heart muscle disease. Heart 1998, 79:599-604.
12. Currie PF, Boon NA: Immunopathogenesis of HIV-related heart muscle disease: current perspectives. AIDS 2003, 17:S21-S28.
13. Luginbuhl LM, Orav EJ, McIntosh K, Lipshultz SE: Cardiac morbidity and related mortality in children with HIV infection. JAMA 1993, 269:2869-2875.
14. Al-Attar I, Orav EJ, Exil V, et al.: Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. J Am Coll Cardiol 2003, 41:1598-1605.
15. Lipshultz SE, Orav EJ, Sanders SP, Colan SD: Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation 1995, 92:2220-2225.
16. Lipshultz SE, Fisher SD, Lai WW, Miller TL: Cardiovascular monitoring and therapy for HIV-infected patients. Ann NY Acad Sci 2001, 946:236-273.
17. Fisher SD, Bowles NE, Towbin JA, Lipshultz SE: Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes. AIDS 2003, 17:S29-S35.
18. Lipshultz SE, Fisher SD, Lai WW, Miller TL: Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 2003, 17:S96-S122.
19. Heidenreich PA, Eisenberg MJ, Kee LL, et al.: Pericardial effusion in AIDS. Incidence and survival. Circulation 1995, 92:3229-3234.
20. Rerkpattanapipat P, Wongpraparut N, Jacobs LE, Kotler MN: Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 2000, 160:602-608.
21. Yunis NA, Stone VE: Cardiac manifestations of HIV/AIDS: a review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:145-154.
22. Bruno F, Sacchi P, Filice G: Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: impact of highly active antiretroviral therapy. AIDS 2003, 17:S83-S87.
23. Bestetti RB, Figueiredo JF, Da Costa JC: Salmonella tricuspid endocarditis in an intravenous drug abuser with human immunodeficiency virus infection. Int J Cardiol 1991, 30:361-362.
24. Daniel WG, Mugge A, Martin RP, et al.: Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med 1991, 324:795-800.
25. Mesa RA, Edell ES, Dunn WF, Edwards WD: Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998, 73:37-45.
26. Aguilar RV, Farber HW: Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000, 162:1846-1850.
27. Jenson HB, Pollock BH: Cardiac cancers in HIV-infected patients. In Cardiology in AIDS. Edited by Lipshultz SE. New York: Chapman and Hall; 1998:255-263.
28. Chu WW, Sosman JM, Stein JH: Clinical cardiac manifestations of HIV infection: a review of current literature. WMJ 2002, 101:40-45.
29. Duong M, Dubois C, Buisson M, et al.: Non-hodgkin's lymphoma of the heart in patients infected with human immunodeficiency virus. Clin Cardiol 1997, 20:497-502.
30. Dal Maso L, Serraino D, Franceschi S: Epidemiology of HIV-associated malignancies. Cancer Treat Res 2001, 104:1-18.
31. Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ: Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1997, 20:2810-2816.
32. Villa A, Foresti V, Confalonieri F: Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res 1995, 5:48-52.
33. Neild PJ, Amadi A, Ponikowski P, et al.: Cardiac autonomic dysfunction in AIDS is not secondary to heart failure. Int J Cardiol 2000, 74:133-137.
34. Becker K, Gorlach I, Frieling T, Haussinger D: Characterization and natural course of cardiac autonomic nervous dysfunction in HIV-infected patients. AIDS 1997, 11:751-757.
35. Wong JCL, Med M, Lipshultz SE: Cardiovascular complications of pharmacotherapeutic agents (excluding the antiretrovirals) in HIV-infected patients. In Cardiology in AIDS. Edited by Lipshultz SE. New York: Chapman and Hall; 1998:331-343.
36. Fantoni M, Autore C, Del Borgo C: Drugs and cardiotoxicity in HIV and AIDS. Ann NY Acad Sci 2001, 946:179-199.
37. Stein KM, Haronian H, Mensah GA, et al.: Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am J Cardiol 1990, 66:888-889.
38. Wharton JM, Demopulos PA, Goldschlager N: Torsade de pointes during administration of pentamidine isethionate. Am J Med 1987, 83:571-576.
39. Cardoso JS, Mota-Miranda A, Conde C, et al.: Inhalatory pentamidine therapy and the duration of the QT interval in HIV-infected patients. Int J Cardiol 1997, 59:285-289.
40. Lipshultz SE, Chanock S, Sanders SP, et al.: Cardiovascular manifestations of human immunodeficiency virus infection in infants and children. Am J Cardiol 1989, 63:1489-1497.
41. Lipshultz SE, Easley KA, Orav EJ et al.: Cardiovascular status of infants and children of women infected with HIV-1 (P2C2 HIV): a cohort study. Lancet 2002, 360:368-373.
42. Fisher SD, Easley KA, Orav EJ, et al.: Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: full-term results from the prospective P2C2 HIV multicenter study. J Am Coll Cardiol 2003, In press.
43. Sullivan JL, Luzuriaga K: The changing face of pediatric HIV-1 infection. N Engl J Med 2001, 345:1568-1569.
44. Pugliese A, Isnardi D, Saini A, et al.: Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000, 40:282-284.
45. Dube MP, Sprecher D, Henry WK, et al.: Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000, 31:1216-1224.
46. Rickerts V, Brodt H, Staszewski S, Stille W: Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000, 5:329-333.
47. Holmberg SD, Moorman AC, Williamson JM, et al.: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002, 360:1747-1748.
48. Harmon WG, Dadlani GH, Fisher SD, Lipshultz SE: Myocardial and pericardial disease in HIV. Curr Treat Options Cardiovasc Med 2002, 4:497-509.
49. Miller TL: Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy. AIDS 2003, 17:S130-S140.
50. Danner SA, Carr A, Leonard JM, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995, 333:1528-1533.
51. Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002, 31:257-275.
52. Hoffmann C, Jaeger H: Cardiology and AIDS-HAART and the consequences. Ann NY Acad Sci 2001, 946:130-144.
53. Scevola D, Di Matteo A, Lanzarini F, et al.: Effects of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2003, 17:S123-S129.
54. Stein JH, Klein MA, Bellehumeur JL, et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:257-262.
55. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and prevention and the American Heart Association. Circulation 2003, 107:499-511.
56. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
57. Hsue P, Lo J, Franklin A, et al.: Increased atherosclerotic progression in patients with HIV. the role of traditional and immunologic risk factors [abstract]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 10-14, 2003.
58. Vittecoq D, Escaut L, Chironi G, et al.: Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 2003, 17:S70-S76.
59. Mooser V: Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS 2003, 17:S65-S69.